Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449286 | 1.00 | EPHX2 (0.31) | EPHX2HSD11B1 | |
| SCHEMBL2451916 | 1.00 | EPHX2 (0.31) | EPHX2HSD11B1 | |
| SCHEMBL20197062 | 0.93 | TSHR (0.31) | — | |
| SCHEMBL428708 | 0.91 | — | — | |
| SCHEMBL31623264 | 0.91 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL28735194 | 0.88 | — | — | |
| SCHEMBL15199170 | 0.83 | POLB (0.32) | HSD11B1 | |
| SCHEMBL13841224 | 0.83 | POLB (0.32) | HSD11B1 | |
| SCHEMBL12332814 | 0.83 | POLB (0.32) | HSD11B1 | |
| SCHEMBL1341780 | 0.83 | CES2 (0.39) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-2881384-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| EP-2364088-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8546359-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2013-03-07 | — | — | US | disclosed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2364088-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010051030-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | EPHX2 2292/4885HSD11B1 2194/4885 |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | FPR1, FPR2, FPR3 | EPHX2 1556/4885HSD11B1 1202/4885 |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | EPHX2 1144/4885HSD11B1 675/4885 |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR3 | EPHX2 3083/4885HSD11B1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.